Extended Data Fig. 3: Selection of the insertion site for Orthogonal-NT2 and validation of its CA125 detection capability. | Nature Sensors

Extended Data Fig. 3: Selection of the insertion site for Orthogonal-NT2 and validation of its CA125 detection capability.

From: Oriented nanobody–field-effect transistor interfaces enable ultrasensitive cancer biomarker detection

Extended Data Fig. 3: Selection of the insertion site for Orthogonal-NT2 and validation of its CA125 detection capability.The alternative text for this image may have been generated using AI.

Selection of the insertion site for Orthogonal-NT2 and validation of its CA125 detection capability. (a) Schematic illustration of the insertion site for the non-natural amino acid N6-[(2-azidoethoxy)carbonyl]-L-lysine introduced into the nanobody NT2 via GCE technology. (b) Normalized current response (ΔI/I0) of SNAP-FET functionalized with Orthogonal-NT2 compared with four random immobilization strategies (via carboxyl and amino) upon exposure to 100 U/mL CA125. Dots represent individual independent samples, and bars indicate mean ± standard deviation (n = 3). (c) Normalized current response ΔI/I0 of NT2-Q13AzK-modified SNAP-FET and bare In2O3 at different CA125 concentrations. Error bars indicate mean ± standard deviation (n = 3).

Source data

Back to article page